To include your compound in the COVID-19 Resource Center, submit it here.

Acceleron, Celgene in anemia deal

Acceleron Pharma Inc. (Cambridge, Mass.) and Celgene Corp. (NASDAQ:CELG) partnered to co-develop and commercialize Acceleron's preclinical anemia candidate ACE-536.

Read the full 195 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE